Prior Authorization Request Form for Repository corticotropin injection (H.P. Acthar Gel)



JOHNS HOPKINS HEALTHCARE

7231 Parkway Drive, Suite 100, Hanover, MD 21076

FAX Completed Form and Applicable Progress Notes to: (410) 424-4037

USFHP Pharmacy Prior Authorization Form

To be completed by Requesting provider		
Drug Name:	Strength:	
Dosage/Frequency (SIG):	Duration of Therapy:	

Questions? Contact the Pharmacy Dept at: (888) 819-1043, option 4

Clinical Documentation must accompany form in order for a determination to be made.

Step	Please complete patient and physician information (please print):				
1	Patient Name:	Physician Name:			
	Address:	Address:			
	Sponsor ID #	Phone #:			
	Date of Birth:	Secure Fax #:			
Step	Please complete the clinical assessment:				
2	 Does the patient have a diagnosis of infantile spasms (West syndrome)? 	☐ Yes Proceed to question 2	☐ No Proceed to question 9		
	2. Will the patient be less than 24 months of age?	☐ Yes	□ No		
		Proceed to question 3	STOP Coverage not approved		
	3. Has the patient received this medication under the TRICARE benefit in the last 6 months? Please choose "No" if the patient did not previously have a TRICARE approved PA for H.P. Acthar Gel	☐ Yes	□ No		
		(subject to verification)	Proceed to question 4		
		Proceed to question 7			
	4. Does the patient have a diagnosis of infantile spasms	☐ Yes	□ No		
	with electroencephalogram (EEG)-confirmed hypsarrhythmia?	Proceed to question 5	STOP		
	nypournyumuu.		Coverage not approved		
	5. Has the patient tried a 2-week course of high-dose (40-60 mg/day) prednisone/prednisolone for any episode of infantile spasms and has failed therapy as evidenced by continued signs/symptoms of either spasms or hypsarrhythmia on EEG?	☐ Yes	□ No		
		Proceed to question 6	STOP		
			Coverage not approved		
	6. Is H.P. Acthar Gel being prescribed by or in consultation	□ Yes	□ No		
	with a pediatric neurologist with expertise in the	Sign and date below			
	management of infantile spasm?	3	STOP Coverage not approved		
			Corolago not approved		

Prior Authorization Request Form for Repository corticotropin injection (H.P. Acthar Gel)

	7. Has the patient demonstrated a clinical response to H.P.	⊔ Yes	⊔ NO
	Acthar Gel as defined by cessation of both previous characteristic spasms AND hypsarrhythmia on EEG within 2 weeks of starting H.P. Acthar Gel?	Proceed to question 8	STOP Coverage not approved
	8. Has the patient demonstrated intolerance to H.P. Acthar Gel, requiring discontinuation of therapy? Note that non-emergent hyperglycemia, weight gain, non-	□ Yes STOP	□ No Sign and date below
	urgent/emergent hypertension, edema, parethesias, insomnia, constipation, diarrhea, hyperphagia, anorexia, nasal/sinus congestion, acne and menstrual irregularities do not meet the threshold for demonstrated intolerance to H.P. Acthar Gel.	Coverage not approved	
	Is the patient an adult older than 18 years of age diagnosed with multiple sclerosis?	☐ Yes Proceed to question 10	☐ No Proceed to question 13
	Has the patient been diagnosed with an exacerbation of multiple sclerosis OR optic neuritis as a specific exacerbation of multiple sclerosis?	☐ Yes Proceed to question 11	□ No Proceed to question 13
	11. Has the patient failed or is intolerant to an adequate trial of IV/PO corticosteroids (e.g., 1000 mg methylprednisolone IV x 5-14 days OR oral equivalent) for the present exacerbation.	☐ Yes Proceed to question 12	□ No STOP Coverage not approved
	12. Is H.P. Acthar Gel being prescribed by or in consultation with a neurologist?	☐ Yes Sign and date below	□ No STOP Coverage not approved
	13. Is H.P. Acthar Gel being prescribed for one of the following uses: optic neuritis not related to MS exacerbation, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Psoriatic Arthritis, Ankylosing Spondylitis, Dermatomyositis, Polymyositis, Juvenile Idiopathic Arthritis, Erythema Multiforme (any severity), Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis Syndrome, Serum Sickness, Keratitis, Iritis, Iridocyclitis, Uveitis, Choroiditis, Birdshot choroiditis, Chorioretinitis, anterior segment inflammation, Nephrotic Syndrome including focal segmental glomerulosclerosis (FSGS), idiopathic membranous nephropathy, IgA nephropathy, membranoproliferative glomerulonephritis (MPGN), and monoclonal diffuse proliferative glomerulonephritis, non-nephrotic edematous states, sarcoidosis, gout, scleritis, or conjunctivitis.	☐ Yes STOP Coverage not approved e sclerosis, or optic neuritis as a s	□ No See note below ¹ specific exacerbation of
Step 3	I certify the above is true to the best of my knowledge. Pleas	e sign and date:	
	Prescriber Signature	Date	[15 August 2019]
For Inter	nal Use Only		
Approv	ved:	Duration of Approval:	month(s)
Denied	d:	Authorized By:	
☐ Incom	plete/Other:	PA#:	
Date Faxe	ed to MD:	Date Decision Render	ed: